Education
About Us
Working with TipRanks
Follow Us
Cingulate Inc (CING)
NASDAQ:CING
CING Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.80 - $20.83
Previous CloseN/A
Volume136.88K
Average Volume (3M)90.91K
Market Cap
$13.97M
Enterprise Value$9.66M
Total Cash (Recent Filing)-$437.19K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta6.85
Next Earnings
May 07, 2025EPS Estimate
-1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.32
Shares Outstanding3,212,233
10 Day Avg. Volume71,825
30 Day Avg. Volume90,913
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.57
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$13.33Price Target Upside206.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Cingulate Inc News
PremiumCompany Announcements
Cingulate Inc. Reports 2024 Financial and Development Milestones
PremiumCompany Announcements
Cingulate Inc. Advances Towards FDA Approval for CTx-1301
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsCTx-1301 showed improvement in Permanent Product Measure of Performance (PERMP) scores, with an industry-leading effect size during Phase 3 study involving adult ADHD patients.
Market OpportunityConsidering the ongoing stimulant shortages, especially for generic stimulant products, and that CTx-1301 only requires one dose, daily, the commercial opportunity for Cingulate is attractive.
Regulatory ProgressCingulate has completed its final FDA-required clinical program for CTx-1301, which is a significant step towards FDA approval for the treatment of ADHD.
Bears Say
RisksRisks for Cingulate include commercial setbacks in ADHD, competition, financing, equity dilution, and regulatory setbacks.
Study ResultsDespite achieving clinical meaningfulness, the Phase 3 study did not achieve statistical significance as it was not powered for this objective.
---
Ownership Overview
63.15% Insiders
0.25% Mutual Funds
0.16% Other Institutional Investors
36.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $1.80 and its highest was $20.83 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $13.97M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is May 07, 2025 which is in 38 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on Mar 26, 2025. The company reported -$1.49 earnings per share for the quarter, missing the consensus estimate of -$1.375 by -$0.115.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -1.62.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 3,212,233 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$1.49 in its last earnings report, missing expectations of -$1.375. Following the earnings report the stock price went up 5.072%.
Which hedge fund is a major shareholder of Cingulate Inc?
Among the largest hedge funds holding Cingulate Inc’s share is GoalVest Advisory LLC. It holds Cingulate Inc’s shares valued at 0.
---
Company Description
Cingulate Inc
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
---
CING Stock 12 Month Forecast
Average Price Target
$13.33
▲(206.44% Upside)
Technical Analysis
Best Analysts Covering CING
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
-54.78%
reiterated a buy rating 27 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -54.78% per trade.
---